Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

Table 5 Univariate analysis of OS for second-line treatment in advanced ESCC patients(\( (\bar x \pm s) \))

Characteristics		n	OS(months)	χ²/F	P
Gender	Male	54	7.30 ± 0.51	0.044	0.833
Gender	Female	6	8.07 ± 3.37	0.044	0.833
Age(years)	≤ 60	36	8.07 ± 0.88	2.684	0.101
Age(years)	>60	24	6.90 ± 1.00	2.684	0.101
Staging	IIIB	5	7.53 ± 0.22	1.513	0.469
	IVA	9	6.70 ± 0.60
	IVB	46	7.30 ± 0.92
ORR	CR + PR	14	15.07 ± 1.68	14.235	<0.001
ORR	SD + PD	46	6.90 ± 0.31	14.235	<0.001
DCR	CR + PR + SD	39	10.03 ± 2.6	6.931	0.008
DCR	PD	21	6.47 ± 0.71	6.931	0.008
T Stage	0	23	6.93 ± 0.45	6.491	0.090
	2	4	12.47 ± 3.97
	3	27	10.03 ± 2.63
	4	6	5.60 ± 1.49
N Stage	0	9	7.10 ± 0.25	0.086	0.993
	1	15	8.63 ± 0.86
	2	9	11.70 ± 6.21
	3	27	6.70 ± 0.52
M Stage	0	15	7.33 ± 0.54	0.148	0.701
M Stage	1	45	7.83 ± 1.03	0.148	0.701
Location	Upper	8	7.53 ± 3.63	0.930	0.628
	Middle	35	8.63 ± 0.83
	Lower	17	6.53 ± 0.41
Differentiation	Poor	7	12.87 ± 5.02	2.805	0.246
	Moderate	51	7.3 ± 0.442
	Well	2	3.30 ± 0.00
PNI Value After 2 Cycles	≥ 45	39	8.67 ± 3.15	5.416	0.020
PNI Value After 2 Cycles	<45	21	7.33 ± 0.43	5.416	0.020
PNI Value Before Enrollment	≥ 45	41	7.33 ± 1.96	1.939	0.164
PNI Value Before Enrollment	<45	19	7.53 ± 0.53	1.939	0.164
Treatment Plan	Chemotherapy	30	6.47 ± 0.46	8.598	0.003
Treatment Plan	Camrelizumab Combined Chemotherapy	30	11.70 ± 2.57	8.598	0.003
Previous Radical Surgery	Yes	27	6.93 ± 0.49	1.937	0.164
Previous Radical Surgery	No	33	10.03 ± 2.59	1.937	0.164
Previous Radical Chemoradiotherapy	Yes	16	8.63 ± 1.13	0.191	0.662
Previous Radical Chemoradiotherapy	No	44	7.23 ± 0.50	0.191	0.662

ISSN: 1477-7819